Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.47 |
| ▸ | NPY1R | P25929 | 7/20 | 0.47 |
| ▸ | NPY2R | P49146 | 5/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194031 | 0.94 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL2198493 | 0.91 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RPLK1 | |
| SCHEMBL2192847 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RPLK1 | |
| SCHEMBL2181939 | 0.90 | DPP7 (0.41) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30585577 | 0.85 | OPRM1 (0.48) | NPY4RNPY1RNPY2RNPY5RPLK1 | |
| SCHEMBL2193514 | 0.84 | DPP4 (0.42) | OPRM1OPRK1 | |
| SCHEMBL2181838 | 0.83 | KDM1A (0.37) | NPY4RNPY1RNPY2RNPY5RPLK1 | |
| SCHEMBL4981729 | 0.82 | DPP4 (0.47) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31481586 | 0.81 | OPRK1 (0.47) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL2182923 | 0.80 | DPP4 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | PTGS2, PTGES2, PTGES | NPY4R 2185/4885NPY1R 3492/4885NPY2R 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.